BioDisruption: The Digest’s 2018 Multi-Slide Guide to Amyris

For many people, a key question in the advanced bioeconomy is: “what is Amyris becoming, and when, and where and how?”

Becoming a global leader in the health and beauty market, and self-funding operations in 2018 with at least $10 million in EBITDA this year — those are the answers appearing out of Emeryville now.

Amyris and its management team gave these two presentations on Q1 2018 results and the outlook from 2018 and beyond in recent weeks — as illuminating overview of Amyris’ promise and progress on multiple fronts.